Untitled
Apixmed Prism — an innovative next-generation genetic analytics platform
Home keyboard_arrow_right Blog keyboard_arrow_right
Is Cancer Hereditary? What Family History Means
Cancer Risks and Genetics
Publication date:
8 minutes reading

Is Cancer Hereditary? What Family History Means

Microscopic 3D illustration of an atypical cell with a glowing core on a light blue background — main cover image for the cancer genetics article.

Cancer can occur across several generations of the same family. When the disease has been diagnosed in parents, siblings, children, or other close relatives, a natural question arises: have other family members inherited a predisposition to cancer?

Yes, cancer cases in one family are sometimes linked to genetic factors. However, this does not always mean the family has a hereditary cancer syndrome: how often cancer occurs can be influenced by common genetic variants as well as by shared habits and living conditions (National Cancer Institute, The Genetics of Cancer, 2024).

So even if a genetic predisposition to certain types of cancer is passed from parents to children, this does not mean the disease will necessarily develop.

How Genetics Is Related to Cancer Development

Cancer arises from an accumulation of changes in cell DNA that disrupt the regulation of cell growth, division, and survival. Some of these changes appear over a lifetime under the influence of age, environment, lifestyle, and random errors during cell division. Such errors are called somatic: they occur in particular cells or tissues and are usually not passed on to offspring (National Cancer Institute, The Genetics of Cancer, 2024).

Other genetic features are present from birth in almost all cells of the body. A pathogenic variant — a genetic change that disrupts the function of a gene and raises the risk of a particular disease — can be inherited from one of the parents. Such changes are called germline, or constitutional.

A germline variant does not mean that cancer will necessarily develop. It may increase the likelihood of the disease, but the degree of that increase depends on the specific gene, the genetic variant, age, sex, and other factors. Even within one family, carriers of the same variant can have different chances of developing cancer: in some it develops during their lifetime, while others may never become ill (National Cancer Institute, The Genetics of Cancer, 2024).

Hereditary predisposition explains only part of cancer cases. According to estimates by the U.S. National Cancer Institute (NCI), up to 10% of all cancers may be linked to inherited genetic changes (National Cancer Institute, The Genetics of Cancer, 2024). At the same time, the share of such cases differs substantially by cancer type. In most cases, cancer develops not because of changes inherited from parents but because of genetic changes that arise and accumulate in individual cells over a lifetime (National Cancer Institute, The Genetics of Cancer, 2024). 

Why Cancer Can Recur in the Same Family

Several cases of cancer among relatives can have different explanations. In itself, this fact does not yet point to a hereditary nature of the diseases.

Hereditary Cancer Syndrome

In some families, an increased risk of certain cancers is linked to inherited pathogenic variants in specific genes. For example, pathogenic variants in the genes

BRCA1 (BRCA1 DNA repair associated) and BRCA2 (BRCA2 DNA repair associated) raise the risk of breast and ovarian cancer and are also linked to an increased risk of prostate and pancreatic cancer (National Cancer Institute, Genetics of Breast and Gynecologic Cancers (PDQ®), 2025).

Another example is Lynch syndrome, which is associated with pathogenic variants in the genes MLH1 (mutL homolog 1), MSH2 (mutS homolog 2), MSH6 (mutS homolog 6), PMS2 (PMS1 homolog 2), as well as with certain deletions (structural mutations) in the gene EPCAM (epithelial cell adhesion molecule). The proteins encoded by the MLH1, MSH2, MSH6, and PMS2 genes take part in the system that corrects errors made when DNA is copied. Disruption of this system promotes the accumulation of genetic changes in cells and raises the risk of, among others, colorectal and endometrial cancer (National Cancer Institute, Genetics of Breast and Gynecologic Cancers (PDQ®), 2025; Idos G et al., GeneReviews®, 2026).

Polygenic Predisposition to Cancer

The risk of developing cancer is also influenced by numerous genetic variants, each of which has only a small effect on its own (National Cancer Institute, Cancer Genetics Overview (PDQ®), 2025). Their combined effect can create a higher or lower genetic predisposition to a particular type of cancer. Such a predisposition can be elevated even when there are no known cases of the disease among relatives (Ji C et al., International Journal of Cancer, 2025).

Shared Living Conditions and Environmental Factors

Relatives may have similar eating habits, levels of physical activity, or workplace conditions, or be exposed to the same carcinogens. Such shared factors can also affect cancer risk in several family members, regardless of whether a hereditary cancer syndrome is present.

Chance Clustering of Cancer Cases in a Family

Common types of cancer can occur in several members of one family without a shared hereditary cause. The probability of such a coincidence grows in large families and with age, because the risk of many cancers rises over the years.

Thus, several cases of cancer in one family may be linked to different factors that act separately or in combination. To assess the possible role of heredity, it is important to consider not only how many relatives have had cancer, but also the tumor types, the age at diagnosis, and the degree of relatedness.

Human chromosome set arranged in pairs inside a petri dish with one illuminated chromosome pair.

What Family History Can Tell You About Cancer Risk

Family history — information about diseases among biological relatives — remains one of the key tools for assessing cancer risk. It helps to spot patterns that may point to a hereditary syndrome or to shared risk factors.

During assessment, it is important to find out:

  • which relatives were diagnosed with cancer, on the maternal or the paternal side
  • which type of cancer was found
  • at what age the diagnosis was made
  • whether one person had several primary tumors
  • whether certain types of cancer recur across several generations.

Particular attention is drawn to cases of cancer at a younger age, multiple diagnoses in one relative, and combinations of certain cancers in one family (National Cancer Institute, Cancer Genetics Overview (PDQ®), 2025). 

For example, a combination of breast and ovarian cancer, or repeated cases of colorectal and endometrial cancer, may be a reason to assess hereditary risk (National Cancer Institute, Genetic Testing for Inherited Cancer Risk, 2024).

At the same time, family history has limitations. Information about relatives may be incomplete, especially if the family is small, some relatives died young, or diagnoses in older generations are unknown (National Cancer Institute, Cancer Genetics Risk Assessment and Counseling (PDQ®), 2025). In addition, family history does not reflect all genetic factors, in particular the combined effect of numerous common genetic variants. Therefore, the absence of cancer cases in a family does not guarantee a low genetic risk. Conversely, several cases of the disease in a family do not prove that a hereditary syndrome is present.

Why No Cancer in the Family Does Not Rule Out a Genetic Predisposition

An increased genetic predisposition can exist even when there are no known cases of cancer among close relatives. This is possible for several reasons:

  1. An inherited pathogenic variant can pass through a generation in which carriers did not become ill. Many hereditary syndromes are characterized by incomplete penetrance — the property of a genetic variant to cause disease in not all of its carriers (National Cancer Institute, Cancer Genetics Overview (PDQ®), 2025). Risk can depend on age and other factors, so the absence of a diagnosis in one parent does not rule out passing the variant to a child.

  2. Common variants with small individual effects can influence genetic predisposition to cancer. Their combined action can raise genetic risk even when there are no cancer cases among close relatives.

  3. Family history is not always complete. Diagnoses may have remained unknown, there may be few relatives, and some cancers more often occur at an older age.

Thus, family history and genetic predisposition describe related but not identical aspects of risk. They are best considered together.

How Genetic Testing Complements Cancer Risk Assessment

Genetic testing makes it possible to assess hereditary predisposition to cancer at different levels: to identify individual pathogenic variants linked to hereditary cancer syndromes, or to determine the combined effect of numerous common genetic variants. These tasks require different approaches, and therefore different genetic testing methods.

Genetic Testing for Hereditary Forms of Cancer

Diagnostic genetic testing looks for rare pathogenic or likely pathogenic germline variants in genes linked to an increased risk of certain cancers. It is ordered, among other cases, when family history or features of the disease point to a possible hereditary syndrome.

If a specific pathogenic variant has already been found in the family, it is possible to check whether other biological relatives have inherited it. If the cause of the clustering of disease in the family has not yet been established, it is usually most informative to test first a relative who has already had the relevant diagnosis. This increases the chances of finding a genetic cause, if there is one (National Cancer Institute, Genetic Testing for Inherited Cancer Risk, 2024).

The results of such testing require correct interpretation. For example, a negative result does not always rule out hereditary risk: it depends on whether the familial genetic cause was known and which genes and variants were examined (National Cancer Institute, Genetic Testing for Inherited Cancer Risk, 2024).

Pathogenic variants should be distinguished separately from variants of uncertain significance (VUS). For the latter, there is not yet enough evidence to determine whether they affect disease risk (National Cancer Institute, Genetic Testing for Inherited Cancer Risk, 2024). A VUS result in itself is not confirmation of a hereditary syndrome and should not be the only basis for changing screening or for preventive surgery.

For more on how accurate genetic tests and their risk estimates are, see the article Genetic Test Accuracy: DNA Reading and Risk Assessment.

Polygenic Cancer Risk Score

Polygenic risk score (PRS) takes into account the combined effect of a large number of common genetic variants, each of which has only a small association with a particular type of cancer on its own. Unlike testing for hereditary syndromes, PRS does not look for a single rare genetic change with a large effect but assesses the overall polygenic predisposition to a specific disease. 

A PRS result usually shows how a person's genetic predisposition compares with values in a reference population — the group of people against which the result is compared (Kachuri L et al., Nature Reviews Genetics, 2024). A higher score means a higher polygenic predisposition relative to that group but does not determine the absolute lifetime risk of the disease (Kachuri L et al., Nature Reviews Genetics, 2024; Lewis CM, Vassos E, Genome Medicine, 2020).

How Genetic Tests for Cancer Differ and Complement Each Other

Testing for hereditary syndromes and polygenic scoring are not interchangeable — they complement each other, because they assess different components of genetic risk.

The difference between the methods, and therefore between the results these tests can provide, has practical significance. For example, a person may have no known cases of cancer in the family but have an elevated polygenic predisposition to a certain tumor type. Or cases of the disease may recur in a family while testing does not find a known pathogenic variant, whereas a polygenic score can help further characterize the contribution of common genetic factors.

Studies show that family history and polygenic scores can provide independent information about risk (Ji C et al., International Journal of Cancer, 2025). At the same time, the potential use of PRS models in clinical decisions depends on the specific type of cancer, the quality of the model, and the evidence for its clinical benefit (Dannhauser FC et al., Journal of Community Genetics, 2024; Lennon NJ et al., Nature Medicine, 2024).

Thus, a polygenic score broadens the picture of the genetic component of risk, particularly when family history does not give a complete answer. Its results should be considered together with other risk factors.

A couple sitting on a sofa in a bright clinical office having a calm consultation with a female doctor.

What to Do If There Have Been Cancer Cases in the Family

If cancer has been diagnosed in several close relatives, the disease occurred at a young age, or one person had several primary tumors, it is worth discussing family history with a doctor. When indicated, the doctor may recommend a consultation with a medical geneticist or a genetic counseling specialist (National Cancer Institute, Genetic Testing for Inherited Cancer Risk, 2024).

Before the consultation, it is useful to gather information about relatives: cancer types, age at diagnosis, the line of relationship, and the results of any previous genetic tests. This will help assess whether there are grounds to suspect a hereditary cancer syndrome.

If a hereditary syndrome is confirmed, further recommendations depend on the specific gene and the level of risk associated with it. They may include an individual surveillance schedule, certain screening methods, or a discussion of preventive measures (National Cancer Institute, Cancer Genetics Overview (PDQ®), 2025). Such decisions are made taking into account clinical guidelines and the person's individual situation.

At the same time, the absence of an identified hereditary syndrome does not mean that genetic factors do not affect risk. Its assessment can take into account not only rare pathogenic variants but also the combined effect of numerous common genetic variants. This is what a polygenic risk score (PRS) allows you to assess. It complements the information from family history, in particular when there are no obvious signs of a hereditary syndrome in the family.

For more on how to act after receiving genetic test results, see the article What to Do With a Genetic Report: From Data to Decisions.

Genetic predisposition to various cancers can be assessed, among other ways, with the DNA test Apixmed Prism “Cancer Risks”, whose results provide additional information about genetic features associated with a predisposition to certain types of cancer.

Genetic results do not determine in advance whether a disease will develop. They are interpreted together with other risk factors so that the further follow-up approach is as well-founded as possible.

 

Genetic test results are not a diagnosis and not a substitute for a doctor's consultation. They reflect individual components of genetic predisposition and must be interpreted together with family history, clinical data, and other risk factors.

 

Sources

  1. National Cancer Institute. The Genetics of Cancer. 2024. https://www.cancer.gov/about-cancer/causes-prevention/genetics
  2. National Cancer Institute. Genetics of Breast and Gynecologic Cancers (PDQ®) – Health Professional Version. 2025. https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq
  3. Idos G, Hampel H, Valle L. Lynch Syndrome. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993–2026. PMID: 20301390. https://www.ncbi.nlm.nih.gov/books/NBK1211/
  4. National Cancer Institute. Cancer Genetics Overview (PDQ®) – Health Professional Version. 2025. https://www.cancer.gov/about-cancer/causes-prevention/genetics/overview-pdq
  5. Ji C, Ge W, Zhu C, et al. Family history and genetic risk score combined to guide cancer risk stratification: A prospective cohort study. International Journal of Cancer. 2025;156(3):505–517. DOI: 10.1002/ijc.35187
  6. National Cancer Institute. Genetic Testing for Inherited Cancer Risk. 2024. https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet
  7. National Cancer Institute. Cancer Genetics Risk Assessment and Counseling (PDQ®) – Health Professional Version. 2025. https://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq 
  8. Kachuri L, Chatterjee N, Hirbo J, et al. Principles and methods for transferring polygenic risk scores across global populations. Nature Reviews Genetics. 2024;25(1):8–25. DOI: 10.1038/s41576-023-00637-2
  9. Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Medicine. 2020;12(1):44. DOI: 10.1186/s13073-020-00742-5
  10. Dannhauser FC, Taylor LC, Tung JSL, Usher-Smith JA. The acceptability and clinical impact of using polygenic scores for risk-estimation of common cancers in primary care: a systematic review. Journal of Community Genetics. 2024;15(3):217–234. DOI: 10.1007/s12687-024-00709-8
  11. Lennon NJ, Kottyan LC, Kachulis C, et al. Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations. Nature Medicine. 2024;30(2):480–487. DOI:10.1038/s41591-024-02796-z

Any questions left?

Leave your contact details — our specialists will contact you shortly. We will help you understand the offers, select a test according to your request, and answer any questions about the product and process.